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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract Cytokine production capacity varies among individuals and depends on cytokine
gene polymorphisms. Transforming growth factor-beta 1 (TGF-b1) plays a significant role in
regulating the proliferation and apoptosis of epithelial cells. Interleukin 10 (IL-10) is an immu-
noregulatory cytokine with biological functions of anti-inflammation, immunosuppression, al-
lergy, and anti-agenesis. The two cytokines are supposed to play an important role in
carcinogenesis. The association between cytokine gene polymorphisms with oral cancer (OC)
was investigated. We studied the association between the polymorphism in TGF-b1 (G to C
polymorphism at codon 25 <þ915>) and IL-10 (1082 G/A, -819 C/T, and 592 C/A) and
the risk of OC in patients (n Z 162) and healthy controls (n Z 118) in Taiwan. All genotyping
experiments were performed using the polymerase chain reaction sequence-specific primer
(PCR-SSP) method. It was found that the codon 25 GC genotype of TGF-b1 is significantly higher
in frequency in patients with OC compared with a healthy control group (p < 0.0001). People
with the GC genotype in codon 25 had an 11.09-fold increased risk of OC [odds ratio
(OR) Z 11.09; 95% confidence interval (CI) Z 6.16e113.23]. IL-10 polymorphisms in 819
and 592 positions correlated with the risk of OC (p < 0.0001). The IL-10 -592 C allele-
containing genotypes posed an increased risk of OC (ORZ 1.79, 95% CI Z 1.11e2.91). People
with the CT genotype in IL-10 -819 had a 3.32-fold increased risk of OC (OR Z 3.32; 95%eclare no conflicts of interests.
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124 H.-J. Hsu et al.CI Z 1.64e6.94). The results suggest that polymorphisms in TGF-b1 and IL-10 may have a sig-
nificant influence on the development of OC.
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reserved.Introduction
Oral cancer (OC) is the sixth most common cancer in the
world with approximately 300,000 new cases diagnosed
annually. Taiwan has the most rapidly increasing incidence
of this disease, and OC is the major cause of cancer-related
death in Taiwanese males aged 25e44 years [1]. Although
the available epidemiological evidence indicates that
smoking and areca nut chewing are major risk factors for
OC, there is a low prevalence rate to development of the
disease [2]. Genetic predisposition might explain this indi-
vidual variability.
Virchow hypothesized that cancer results from inflam-
mation caused by prolonged irritation, tissue injury, and
activation of a local host response that favors cell prolif-
eration [3]. Cytokines may have important roles in the
carcinogenesis of various malignant solid tumors.
Transforming growth factor-b (TGF-b) has important
roles in regulating cell growth, differentiation, apoptosis,
adhesion, and motility. The TGF-b pathway regulates many
of these cellular processes, and alterations in the signaling
cascade in cancer patients may promote tumor develop-
ment [4]. All three isoforms (TGF-b1, -b2, and -b3) of TGF-b
have tissue-specific expressions and each is encoded by a
distinct gene. The inhibitory effects of TGF-b1 in head and
neck squamous tumors have been determined mainly in
cultured cell lines [5]. In vivo studies indicate that TGF-b1
induces tumor regression through Smad4-independent
pathways that sensitize keratinocytes to mitochondrial-
mediated apoptosis [6]. The TGF-b1 gene is located on
chromosome 19q13. Single nucleotide polymorphisms
(SNPs) in cytokine genes may affect cytokine expression or
function via the cytokine network. Many SNPs have been
evaluated for possible roles in inflammatory diseases and
cancer predisposition. A TGF-b1 polymorphism located on
codon 25 (G/C) of exon 1 encodes the leader sequence of
the protein and has an importance functional role in
modulating its transmembrane transport.
Interleukin 10 (IL-10) is an immunoregulatory cytokine
with biological functions such as anti-inflammation,
immunosuppression, allergy, and anti-agenesis. It oper-
ates through the Janus kinaseesignal transducer and acti-
vator of transcription (JAKeSTAT) signaling pathway by
blocking nuclear factor-kappa-B (NF-kB) nuclear trans-
location [7]. Although macrophages are the major source of
IL-10 in normal tissues, IL-10 can also be produced by T
lymphocytes, B lymphocytes, mast cells, eosinophils, or
even keratinocytes [8]. The IL-10 gene spans about 4.7 kb
on chromosome 1q21-32 and contains five exons and four
introns [8]. In head and neck carcinomas, higher than
normal IL-10 expression in serum or tumor tissue is associ-
ated with poor prognosis [9].The cytokine IL-10 also has an important role in tumor-
igenesis. Promoter polymorphisms may be subject to the
effects of gene transcription and protein production. The
IL-10 -1082 SNP and 1082, -819, -592 haplotype is
reportedly associated with differential IL-10 expression
in vitro, and the 1082 A,-819 T, -592 A haplotype is
associated with lower IL-10 expression in comparison with
the 1082 G, -819 C, -592 C haplotype [10]. Polymorphisms
in the IL10 promoter are associated with increased risk of
lung and gastric cancers, lymphoma, and hepatocellular
carcinoma [11e15].
To the best of our knowledge, whether TGF-b1 and IL-10
gene polymorphisms are associated with OC risk has not
been studied in the Taiwanese population. Therefore, the
aim of this study was to examine whether gene poly-
morphisms of TGF-b1 (codon 25: G/C) and IL-10 (1082 G/
A, -819 C/T, and 592 C/A) may affect susceptibility to OC.Methods
Recruitment of study participants
The participants were OC patients recruited between April
2003 and November 2006. The male controls were recruited
between March 2005 and November 2006. The final popu-
lation included 162 OC patients who were treated at the
Department of Oral and Maxillo-facial Surgery of Chung-Ho
Memorial Hospital, Kaohsiung Medical University, Kaoh-
siung, Taiwan and who gave informed consent to this study.
The healthy male control group comprised 118 consecutive
volunteers who attended an annual health check-up. All OC
patients were diagnosed histologically with incisional bi-
opsy or surgical specimen. The clinical stages were cate-
gorized according to the Tumor-Node-Metastasis (TNM)
system. In cases who had received radical surgery, the final
pathological stage was applied. In cases who had not
received surgery, the clinical stage was applied. Patholog-
ical grades of the OC were classified using Broder’s criteria
as follows: Grade I, tumors showing a marked tendency to
differentiation, with at least three-fourths of their cells
differentiated; Grade II, tumors with three-fourths to one-
half of their cells differentiated; Grade III, tumors with
one-half to one-fourth of their cells differentiated; Grade
IV, tumors with one-fourth to none of their cells differen-
tiated. Trained interviewers used a standard questionnaire
to collect demographic data from each participant,
including history of exposure to risk factors such as betel
quid chewing, cigarette smoking, and alcohol drinking.
After obtaining written informed consent, 10-mL blood
samples were drawn into coded ethylene diamine tetra-
acetate (EDTA) tubes. Participants who smoked at least
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applied to drinkers and betel quid chewers. The experi-
mental protocol was approved by the Institutional Review
Board of Kaohsiung Medical University Hospital.
DNA isolation and cytokine genotyping
Genomic DNA was extracted from whole EDTA-treated pe-
ripheral blood using a QIAamp Blood Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
SNPs were analyzed in TGF-b1 and IL-10 for genotype
assignment. Single nucleotide mutations in the coding re-
gion were surveyed for TGF-b1: codon 25 rs1800471, either
C or G. Three different polymorphisms were examined for
the IL-10 promoter region: position 1082 rs1800896 (G vs.
A), position 819 rs1800871 (C vs. T), and position 592
rs1800872 (A vs. C). Cytokine genotyping was performed by
the polymerase chain reaction sequence-specific primer
(PCR-SSP) method by using a commercially available kit
(One Lambda, Inc., Canoga Park, CA, USA) in accordance
with the manufacturer’s instructions. All PCR products
were visualized after electrophoresis on a 2% agarose gel
and ethidium bromide staging. The DNA extractions and
PCR amplifications were performed by a technician blinded
to the study groups.
Statistical analysis
JMP software Version 9 (SAS Institute Inc., Cary, NC, USA)
for Microsoft Windows was used for all statistical analysis,
including determinations of the mean and standard error of
numeric variables. The HardyeWeinberg equilibrium of
each genetic polymorphism was tested using a goodness-of-
fit c2 test to compare observed genotypes frequencies with
those in healthy controls. Two-sample t tests or c2 tests
were used as needed to compare means and proportions
between the control group and the OC group as needed. To
determine whether cytokine genotype and allele frequency
were associated with cancer risk, the significance of the
difference in distributions of genotypes and alleles be-
tween patients and control participants was calculated by
the c2 statistic or Fisher’s exact test and presented as a p
value. All p values were two-sided. A p value < 0.05 was
considered statistically significant. Associations between
TGF-b1 genotypes and diseases were analyzed by logistic
regression of patients versus controls. Independent vari-
ables were adjusted to control for potentially confounding
effects of age, smoking, drinking status, and duration of
betel quid chewing. Logistic regression was performed by
JMP statistical software.
Results
Table 1 shows the clinicopathological features of the pa-
tients. Of the 162 patients in this study, 125 (77.16%) were
male and 37 (22.84%) were female. The two groups signif-
icantly differed in mean age, sex distribution, and use of
betel quid, alcohol, and tobacco. The age range of the
patients with OC was 23e85 years old [median age, 52.04
years old; 95% confidence interval (CI), 40.41e63.67 years].
The age range of the healthy controls was 23e83 years(median age, 59.2 years; 95% CI, 46.29e72.11 years). More
than 73% patients had a history of habitual betel nut
chewing.
The buccal mucosa (45.68%) was the most commonly
affected site of OC (Table 1), and 91.36% of patients had
squamous cell carcinoma of the oral cavity. Ten patients
(6.17%) had verrucous carcinoma. The remainder (2.47%)
had other malignancies. Most (62.96%) had advanced dis-
ease (Stage III/IV), and 37.04% of cases had Stage I or Stage
II tumors. Histological differentiation in all patients
revealed that the tumors were well differentiated in 87.04%
and moderately differentiated in 4.32%. No patients had
poorly differentiated tumors.
The control group genotype data for all SNPs were
analyzed for fitness in HardyeWeinberg equilibrium. No
cases showed significant deviation.Association between TGF-b1 and OC risk
The high producer GG (Arg/Arg) genotype at codon 25 was
found in 53% (84/158) of OC patients and in 92.74% of the
healthy controls (Table 2). The intermediate producer GC
(Arg/Pro) genotype was present in 74/158 (46.84%) of the
OC patients and in 8/124 (6.45%) of the healthy controls.
Only one person in the control group and no patients in the
OC group had the low producer CC (Pro/Pro) genotype. The
percentage of participants with the high producer G (Arg)
allele significantly differed between the OC group (76.58%)
and the control group (95.97%) (p < 0.0001). The fre-
quencies of the C allele were 23.42% in the OC group and
4.03% in the control group. The groups significantly differed
in polymorphisms at codon 25 of TGF-b1 gene (p < 0.0001).
Participants with TGF-b1 codon 25 C-allele containing ge-
notypes GC or CC had a higher OC risk [adjusted odds ratio
(OR) Z 11.09, 95% CI Z 6.16e113.23, p < 0.0001]
compared to those with the GG genotype.Association between IL-10 and OC risk
The 1082 A/G polymorphism of the IL-10 gene did not
significantly differ between the OC and control groups.
However, the 819 C/T and 592 C/A polymorphic sites
significantly differed (Tables 2,3). The ‘T’ allele was found
more frequently in both the OC and control groups (0.58
and 0.70, respectively) compared to the ‘C’ allele at 819.
However, the frequency of the ‘C’ allele, known as the high
producing allele, was more common in the OC group (OR
1.79, 95% CI 1.11e2.91, p Z 0.0158) and also the TC ge-
notype was more frequent whereas the TT genotype was
statistically less common in the OC group compared to the
control group (OR 3.32, 95% CI 1.64e6.94, pZ 0.0008). The
‘A’ allele was found more frequently in both the OC and
control groups (0.58 and 0.70, respectively) compared to
the ‘C’ allele at 592. However, the ‘C’ allele, known as
the high producing allele, occurred more frequently in the
OC group (OR 1.79, 95% CI 1.11e2.91, pZ 0.0158) and also
the TC genotype was more frequent, whereas the TT ge-
notype was statistically less common in the OC group
compared to the control group (OR 3.32, 95% CI 1.64e6.94,
p Z 0.0008).
Table 1 Characteristics of the study population.
Characteristic Cases (n Z 162) Value p
Controls (n Z 118)
Age (y)
Range 23e85 23e83
Average 52.70  12.38 59.20  12.91 0.0018 *
 55 106 (65.43%) 49 (38.28%)
> 55 56 (34.57%) 79 (61.72%)
Sex < 0.0001 *
Male 125 (77.16%) 77 (60.16%)
Female 37 (22.84%) 51 (39.84%)
Betel quid chewing status (%) < 0.0001 *
Ever 119 (73.46%) 22 (17.19%)
Never 43 (26.54%) 106 (82.81%)
Alcohol drinking consumption status (%) < 0.0001 *
Ever 112 (69.14%) 32 (25%)
Never 50 (30.85%) 96 (75%)
Smoking status (%) < 0.0001 *
Ever 116 (71.60%) 38 (29.69%)
Never 46 (28.42%) 90 (70.31%)
Site
Tongue 38 (23.46%)
Buccal mucosa 74 (45.68%)
Floor of mouth 4 (2.47%)
Alveolus 17 (10.49%)
Lips 16 (9.88%)
Retromolar trigone 7 (4.32%)
Palate 6 (3.70%)
Tumor size
T1 þ T2 111 (68.52%)
T3 þ T4 51 (31.48%)
Lymph node involvement
N0 79 (48.77%)
N1 56 (34.57%)
Distant metastasis
M0 162 (100%)
M1 0 (0%)
Clinical stage
Early stage (I þ II) 60 (37.04%)
Late stage (III þ IV) 102 (62.96%)
Pathological diagnosis
Squamous cell carcinoma
Well differentiated 141 (87.04%)
Moderate differentiation 7 (4.32%)
Poor differentiation 0 (0%)
Verrucous carcinoma 10 (6.17%)
Other malignancy 4 (2.47%)
* Statistically significant difference between patients and control subjects (p < 0.05).
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dividuals were further divided into low (ATA/ATA, ACC/
ATA, ACC/ACC), intermediate (GCC/ACC, GCC/ATA), and
high (GCC/GCC) producer genotypes. The frequency of
high/intermediate producer genotypes did not significantly
differ in either the OC group or in the control group
(10.34%, 14.29%, respectively, p Z 0.3381). The low pro-
ducing genotype also showed no significant difference be-
tween the two groups (Table 4).Discussion
Betel quid chewing and smoking are known to be important
risk factors for oral squamous cell carcinoma and precan-
cerous lesions, including oral submucous fibrosis (OSF) and
leukoplakia (OL) [16]. The data in our study were consistent
with the literature.Betelquidchewingandsmokingwerehigh
risk factors and males were more susceptible than females.
After nominal logistic regression analysis of the data,
Table 3 Distributions of combined polymorphisms at different positions of IL-10.
Cytokine gene polymorphism Cases, n (%) Controls, n (%) p
IL-10 (1082, 819, 592) a
GCC/GCC 1 (0.69%) 0 (0.0)
GCC/ACC 2 (1.38%) 5 (4.46%)
GCC/ATA 12 (8.28%) 11 (9.82%)
ACC/ACC 8 (5.52%) 3 (2.68%) 0.0002 *
ACC/ATA 89 (61.38%) 40 (35.71%)
ATA/ATA 33 (22.76%) 53 (47.32%)
ACA/ATA 0 (0.0) 0 (0.0)
ATC/ATA 0 (0.0) 0 (0.0)
GCC/ATC 0 (0.0) 0 (0.0)
* Statistically significant difference between patients and control subjects (p < 0.05).
CI Z confidence interval; IL-10 Z interleukin 10; n.s. Z not statistically significant (p > 0.05); OR Z odds ratio.
a Due to some technical problems, the genotyping results of 165 patients and 112 controls were included.
Table 2 Distribution and allele frequency of TGF-b1 (codon 25), IL-10 (1082, 819, 592) among OC patients and healthy
controls.
Cytokine gene Genotype
frequency (%)
Cases Controls p Adjusted OR
(age, sex, habits)
95% CI p
TGF-b1 (codon 25)
CC 0 (%) 1 (0.81%) < 0.0001 * 5.074E-07 0.00e4.90 n.s.
GC 74 (46.84%) 8 (6.45%) 11.09 6.16e113.23 < 0.0001 *
GG 84 (53.16%) 115 (92.74%) 1.00
C 74 (23.42%) 10 (4.03%) < 0.0001 * 5.76 2.66e13.61 < 0.0001 *
G 242 (76.58%) 238 (95.97%) 1.00
IL-10 (1082)
GG 1 (0.69%) 0 (0%)
GA 14 (9.66%) 16 (14.29%) n.s.
AA 130 (89.66%) 96 (85.71%)
G 16 (5.52%) 16 (7.14%) n.s. 0.76 0.31e1.87 n.s.
A 274 (94.48%) 208 (92.86%) 1.00
IL-10 (819)
CC 11 (7.59%) 8 (7.14%) < 0.0001 * 2.46 0.69e9.10 n.s.
CT 101 (69.66%) 51 (45.54%) 3.32 1.64e6.94 0.0008 *
TT 33 (22.76%) 53 (47.32%) 1.00
C 123 (42.41%) 67 (29.91%) 0.0034 * 1.79 1.11e2.91 0.0158 *
T 167 (57.59%) 157 (70.09%) 1.00
IL-10 (592)
CC 11 (7.59%) 8 (7.14%) < 0.0001 * 2.46 0.69e9.10 n.s.
CA 101 (69.66%) 51 (45.54%) 3.32 1.64e6.94 0.0008 *
AA 33 (22.76%) 53 (47.32%) 1.00
C 123 (42.41%) 67 (29.91%) 0.0034 * 1.79 1.11e2.91 0.0158 *
A 167 (57.59%) 157 (70.09%) 1.00
* Statistically significant difference between patients and control subjects (p < 0.05).
CI Z confidence interval; IL-10 Z interleukin 10; n.s. Z not significant; OC Z oral cancer; OR Z odds ratio; TGF-b1 Z transforming
growth factor-beta 1.
Table 4 Cytokine gene polymorphisms and their associated phenotypes.
Cytokine gene polymorphism Cases, n (%) Controls, n (%) p *
IL-10 (1082, 819, 592) a
High/intermediate 15 (10.34%) 16 (14.29%) n.s. (0.3381)
Low 130 (89.66%) 96 (85.71%)
* Statistically significant difference between patients and control subjects (p < 0.05).
CI Z confidence interval; IL-10 Z interleukin 10; n.s. Z not statistically significant (p > 0.05); OR Z odds ratio.
a Due to some technical problems, the genotyping results of 165 patients and 112 controls were included.
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chewing, a protective factor was identified in males
(ORZ 0.12; 95%CIZ 0.07e0.42). In theabsenceofbetel quid
chewing, females are more susceptible to oral diseases
compared to males. In males, the higher incidence of oral
mucosa diseases results from the stronger tendency to
consume substances such as tobacco, alcohol, andbetel quid.
Interestingly, not all betel quid chewers develop oral
mucosal lesions [2]. Inherited differences in the effective-
ness of the disease may play an important role in host sus-
ceptibility. Acrolein in cigarette smoke inhibits the T cell
response [17]. The interaction between genetic factors of
the immune system and oral consumption of tobacco,
alcohol, andbetel quid is interesting andneeds further study.
This study also compared the TGF-b1 allele frequencies
at codon 25 in Taiwan with those reported in other ethnic
groups. In Hong Kong Chinese, the prevalence of codon 25 G
appeared to be lower, and that of codon 25 C appeared to
be higher. In Caucasians, the prevalence was similar [18].
The differences may be related to the governance of
Taiwan by many different countries.
This study revealed an increased risk of the C allele at
codon 25 with respect to the G allele in patients with OC.
The GC genotype was significantly higher in the OC group
than in the controls and appeared to be associated with an
11.9-fold increased risk as compared to the wild type GG
genotype.
TGF-b is a potent anti-inflammatory cytokine that reg-
ulates cell proliferation, cell differentiation, intercellular
adhesion, apoptosis, wound repair, and tissue recycling.
The TGF-b signal transduction cascade from the cytoplasm
to the nucleus involves a novel family of proteins called
Smads [4,19,20]. The associations between TGF-b1
expression and cancer development and progression are
complex. Mutations resulting in the Smad signaling proteins
decrease overall survival [21]. Overexpression of TGF-b1
confers resistance to induced carcinogenesis, which sug-
gests a tumor-suppressant function of TGF-b [22]. Absence
of TGF-b1 expression is associated with a high risk of ma-
lignant conversion of skin tumors in mice [23].
To our knowledge, this study is the first to report prev-
alence data for polymorphisms of the TGF-b1 gene in a
Taiwan population and is the first to investigate an associ-
ation between such polymorphisms and OC. Since codon 25
of TGF-b1 increases serum levels of TGF-b1 in the presence
of the G allele, it might contribute to long-term suppression
of epithelium proliferation and might decrease OC risk. The
C allele at codon 25 may reduce suppression of the
epithelium proliferation, which increases OC risk. TGF-b1
low-production genotypes not only increase the risk of
breast cancer [24], but are also associated with an
increased risk of breast cancer relapse [25] and a reduced
5-year disease-free survival rate [26]. TGF-b1 inhibits the
expression of the early viral transforming regions E6 and E7,
which are key oncoproteins. Studies suggest that squamous
cell carcinomas are devoid of TGF-b1, which raises the
possibility that elevated levels of this growth factor could
protect against cervical cancer [27].
The findings of this study suggest that IL-10 poly-
morphism might have an important role in increasing OC
risk. Compared to the control group, the OC group had
more heterozygote genotypes (C/T and C/A) at positions819 and 592, respectively. The results published by
Vairaktaris et al [28] regarding the role of IL-10 -1082 A/G
polymorphism in the pathogenesis of oral squamous cell
carcinoma revealed a strong association with increased OC
risk. The discordance between these two studies might be
explained by different patient characteristics. For
example, Vairaktaris et al included 144 cases and 141
controls from Greek and German populations whereas all
patients in our study were Asian. Since polymorphisms are
known to vary by ethnicity, data from studies of different
ethnic populations must be interpreted cautiously. In
another report published by Yao et al [29], analysis of the
role of polymorphisms of the IL-10 promoter gene in the
1082, -819, and 592 positions, revealed that the 1082
G allele carriers are associated with a significantly
increased risk of OC as compared with the 1082 A allele.
However, genotype and allele frequencies of the IL-10
promotor 819 T/C and 592 A/C polymorphisms in OC
patients did not significantly differ from those in healthy
controls in that study. In our study, the IL-10 promoter gene
in the 1082 position showed no association with OC risk.
However, the IL-10 -819 C allele and 592 C allele were
associated with a higher risk as compared to the 819 T
allele and the 592 A allele. The distribution of the grade
of tumor differentiation also differed. Histological differ-
entiation of the cancers was available in all patients
analyzed in our study. Well-differentiated tumors were
present in 87.04% of the samples; the remainders were
moderately differentiated (4.32%) and no patients had
poorly differentiated tumors. Yao et al [29] reported well-
differentiated tumors in 14.6% of cases. The tumors were
moderately differentiated in 23.9% of cases and poorly
differentiated in 61.4% of cases. Differentiation often af-
fects outcome of treatment and prognosis. The differences
are interesting and need further study. Yao et al did not
report betel quid chewing status. However, betel quit
chewing status was one of the most important etiologies in
our OC patients, and 73.46% previously chewed betel quid.
Possible explanations are differences in the ethnicity,
allelic distribution, and clinical features of the patients.
Further studies are needed to clarify the relations between
betel quid chewing habit and IL-10.
For development of OC, environmental factors are more
important than SNPs. Analyses of the role of SNP in OC
patients who used alcohol, tobacco, and betel quid showed
no interaction between polymorphisms of IL-10 and TGF-b1
and oral habits such as smoking, alcohol consumption, and
betel quid chewing (data not shown). This may explain why
some patients who did not have the risk factors of smoking,
betel nut chewing, and alcohol drinking still developed OC.
The analytical results suggest that the intrinsic, geneti-
cally determined ability to produce high or low levels of
TGF-b1 as represented by G/C polymorphisms at codon 25
and polymorphisms of the IL-10 gene (819 T/C and 592
A/C) is the critical factor in the development of OC.References
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